Study #2021-0520
A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab, Ipilimumab, Cabozantinib
Description
A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Brain Metastases, Renal Cell Carcinoma
Study phase:
Phase II
Physician name:
Jianbo Wang
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-773-0951
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.